Dr. Horton Interview on Pathology, Part 3: Transitioning to Molecular Pathology

February 6, 2010 - 10:25 am email to a friend      Print This Post     view / write comments

(1 votes, average: 5.00 out of 5)

 Loading ...

Dr West

This is the last part of my discussion with Dr. Matthew Horton, a pathologist with a special training and a great expertise in lung pathology who works here in Seattle at a company called CellNetix.

We focus in this last one on the increasing focus on molecular markers in making clinical decisions and how this is changing the relationship of pathologists with oncologists, as well as the need for pathologists to provide this information in a timely way.

dr-horton-pt-3-transition-to-molecular-pathology-audio-podcast

dr-horton-pt-3-transition-to-molecular-pathology-transcript

dr-horton-pt-3-transition-to-molecular-pathology-figures

Next, we’ll turn to coverage of imaging issues in cancer management.

Podcast: Play in new window | Download

Related posts:

1. Interview with Dr. Matthew Horton, Pathologist, Part 2: Neuroendocrine Lung Tumors & Bronchioloalveolar Carcinoma This is a
2. Interview with Lung Cancer Pathologist Matthew Horton, Pt 1: Intro to NSCLC Subtypes I had the
3. Podcast of Q&A Portion from Molecular Markers Webinar with Dr. Pennell    Here
4. Interview: Dr. George Simon on Molecular Markers for Chemo Effectiveness in Lung Cancer My friend
5. Dr. Pennell on Emerging Molecular Markers in NSCLC Management: Podcast Now Available    We kn

Related posts brought to you by Yet Another Related Posts Plugin.

Posted in: EGFR mutations and other molecular markers, Pathology/Lung Cancer Subtypes email to a friend  Print This Post